
BioMendics Begins TAMES-02 Trial for New EBS Therapy
BioMendics Launches Landmark TAMES-02 Clinical Trial to Advance First-in-Class Therapy for Epidermolysis Bullosa Simplex BioMendics, a clinical-stage biopharmaceutical company specializing in the development of novel therapies for rare dermatologic conditions,…












